Health & Fitness
Wed, August 18, 2010Tue, August 17, 2010Mon, August 16, 2010Fri, August 13, 2010Thu, August 12, 2010Wed, August 11, 2010Tue, August 10, 2010Mon, August 9, 2010Fri, August 6, 2010Thu, August 5, 2010Wed, August 4, 2010Tue, August 3, 2010Mon, August 2, 2010Fri, July 30, 2010Thu, July 29, 2010Wed, July 28, 2010Tue, July 27, 2010RXi Pharmaceuticals to Host Second Quarter 2010 Conference Call on Wednesday, August 11, 2010
Published in Health and Fitness on Friday, August 6th 2010 at 4:27 GMT by Market Wire
WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced that it will release financial results for the quarter ended June 30, 2010 on Wednesday, August 11, 2010, before the U.S. financial markets open.
Management will provide an update on the company and discuss financial results on a conference call scheduled for Wednesday, August 11, 2010 at 10:30 am ET. To access the call, please dial 866-783-2137 (domestic) or 857-350-1596 (international) five minutes prior to the start time and provide the passcode 92650464. A replay of the call will be available beginning at 1:30 pm ET on August 11, 2010. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international), and provide the passcode 84592415.
A live audio of the conference call can also be accessed from the companya™s website at [ www.rxipharma.com ]. A link to the webcast may be found in the Investor Relations section of the website. An archived audio webcast will be available on RXia™s website approximately 2 hours after the event.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. [ www.rxipharma.com ]
